Anti-cancer agents with benzophenanthridine structure and preparations containing them

FIELD: medicine, pharmaceutics.

SUBSTANCE: there are presented: using benzophenanthridine alkaloid salts for preparing therapeutic agents for treating tumours, wherein the alkaloid salt is found in the form luteic, phosphatidic or hyaluronic acid, the benzophenanthridine alkaloid salt with phosphatidic acid or hyaluronic acid, and a based pharmaceutical composition for treating tumours.

EFFECT: what is shown is cytotoxic activity of the sanguinarine salts according to the invention at least twice increased in all studied tumour cell lines in relation to the chloride salt; it is suggested to be caused by higher absorption by the tumour cells.

12 cl, 8 ex


The present invention relates to the use of benzophenantridin alkaloids and their salts to obtain drugs for the treatment of tumors.

The invention also relates to new salts of the above-mentioned alkaloids containing compositions.

The level of technology

The first target for Oncology is the complete destruction of the tumor by any means, even if it causes serious side effects; the motto of primum non nocere ("first do no harm") is not used as a guide in the treatment of tumors, however, are preferably replaced by primum succerere ("hurry to help").

Cancer treatment usually involves radical surgery, targeted radiotherapy, including photodynamic therapy, large doses of drugs for chemotherapy, radiotherapy and treatment with cytokines (IL2) and monoclonal antibodies. Despite the large, ever-increasing the number of available treatments, the success rate from the point of view of recovery is still unsatisfactory, especially in the case of chemotherapy, because of the emergence of drug resistance.

In solid tumors chemotherapy quickly reduces the mass of the tumor, but not completely; because of the small number of extremely drug-resistant tumor cells can remain active and then to develop, often with fatal outcome. These cells have recently been called trunks the x tumor cells, which have significant potential for proliferation and adaptability. Mentioned cells constitute approximately 5% of the tumor mass and are resistant to all known at the moment tools of chemotherapy. The existence of tumor stem cells was first shown for myeloid leukemia (Bonnet D, Dick JE. Nature Medicine, 3, 730-737 (1997)) and subsequently installed for tumors of the breast and brain (Al-Hajj M, et al., Natl Acad. Sci., USA, 100. 3983-3988, 2003 Sing SK, et al., 432, 396-401, Nature 2004).

Recently, stem cells have been isolated from melanomas, tumors of the colon and lung slices (Ricci-Vitali, Nature 445, 111-115 (2007); D. Fang, Cancer Res., 65, 9328-9337 2005, 'eramo, Cell Death and Differentiation advance online publication, Nov 30. 2007 Doi: 10.1038/sj.cdd.4402283).

These cells, as mentioned above, are not controlled by conventional treatment and regenerate the tumor. Consequently, there is an urgent need for the development of compounds able to inhibit stem tumor cells, possibly through induction of apoptosis.

Description of the invention

At the moment it is known that benzophenantridin alkaloids, especially sanguinarine, chelerythrine, chelidonine and their salts luteomas, phosphatide or hyaluronic acids exert an antiproliferative effect on multidrug-resistant tumor stem cells in.

In particular, salt luteomas acid provide a strong cytotoxic effect against cancer to ATOC and the same strong antiangiogenic, anti-inflammatory and analgesic effect.

Thus, the first object of the invention relates to the use of benzophenantridin alkaloids and their salts to obtain drugs for the treatment of tumors.

A second object of the present invention provides a new salt benzophenantridin alkaloids and phosphatide or hyaluronic acid. Mentioned salts are particularly useful for targeting local or systemic injection.

In an additional aspect, the invention provides complexes benzophenantridin or isoquinoline alkaloids with human albumin in the form of nanoparticles and dispersions containing the above-mentioned complexes, which can be administered intravenously or orally. Nanoparticles selectively reach the tumor, where they exert cytotoxic and antiangiogenic effect of reducing the mass of the tumor. This drug is particularly useful for the treatment of solid tumors and more conventional forms of leukemia.

Phosphatidic acid contain residues of fatty acids, which may be the same or different, saturated or unsaturated unbranched chains containing 12-22 carbon atoms.

Preferred dipalmitoyl and distearoylphosphatidylcholine acid, which significantly increase oral and local bioavailability.

Particularly preferred salts of sanguinarine is with phosphatidic acid.

Salts according to the invention is able to induce apoptosis of tumor stem cells in submicromolar concentrations.

In vitro it was shown that salt sanguinarine and luteomas acid has a strong inhibitory effect against melanoma and stem cells of the colon at a concentration of 200 ng/ml. Her behavior towards other cancer stem cells is identical. These alkaloids can therefore be regarded as antitumor agents of a new generation, able to effectively treat tumors of the person. For tumors of the colon, liver, pancreas and cervix the most appropriate form is a salt with luteomas acid, dispersed in a suitable carrier, whereas for the treatment of skin tumors, such as melanoma, can successfully enter the salt of phosphatidic acid topically directly on the area affected by the tumor.

Complexes with albumin suitable for the introduction using Loco-regional injection at a dose much lower than the toxic dose, and over very long periods; the selectivity to stem tumor cells compared with normal cells and a strong antiangiogenic effect leads to a rapid reduction and possible elimination of the tumor.

More suitable for oral and topical introduction is salt sanguinarine, luteo the Oh of the acid. It is shown that the said salt is especially effective in the treatment of oropharyngeal cavity, head and neck tumors, melanoma and tumors of the cervix, to a greater extent than the alkaloids that are not associated with the acid, plus it affects any viruses associated with cancer.

Also useful salts of hyaluronic acid, increasing the intake of alkaloid cell and allowing it to destroy the tumor.

The preparations obtained in the course of well known processes such as described in "Remington''s Pharmaceutical Handbook", Mack Publishing Co., N.Y., USA, together with suitable excipients.

The examples below illustrate details of the invention.

Example I to Obtain salt luteomas acid and sanguinarine

3,68 g of sanguinarine chloride dissolved in 100 ml of ethanol, while stirring, 3.6 g of luteolata potassium, the mixture react for 3 hours the Formed potassium chloride is filtered off and the solution concentrated to a small volume. Obtain 5.6 g of salt.

Example II to Obtain salts of sanguinarine and 1,2-dipalmitoyl-sn-glycero-3-phospho-rac-(1-glycerol)

3.7 g of sanguinarine chloride dissolved in 50 ml of methanol; this solution with stirring, 7.5 g of sodium salt of 1,2-dipalmitoyl-sn-glycero-3-phospho-rac-(1-glycerol)-1,2-dipalmitoyl-sn-glycero-3-phospho-rac-(1-glycerol), and the mixture is left for 2 hours under stirring. The resulting solution was diluted with equal about what yamam of methylene chloride and the mixture is left for 0.5 hour with stirring. Precipitated sodium chloride is filtered off and the filtrate is concentrated until dry under vacuum at a temperature not exceeding 35C. Receive 10 g of brown solid substance having a melting point of 70C.

Example III - Receiving albumin nanoparticles with chelerythrine

1 g of chelerythrine dissolved in 15 ml of dioxane at room temperature and added to a solution of 5 g of human albumin in 300 ml of saline solution. The mixture is left under stirring in a sterile atmosphere for 4 h the Resulting opaque solution was exposed to ultrasound for 1 minute. The physical appearance and color of the suspension changes. The solution is dried by sublimation without the addition of excipients.

Example IV

In accordance with the procedures of example III get the solution of chelerythrine and dried by sublimation under sterile conditions in a container, which contains 10 mg of chelerythrine after the process is complete.

The lyophilisate is used in Loco-regional treatment of tumors of the oropharyngeal cavity.

Example V - Anagramania chewable tablets for the treatment of head and neck tumors

Luteal sanguinarine10,00 mg
Soy lecithin30,00 mg
Anhydrous whether the traditional acid 10,00 mg
Lactose240,00 mg
Mannitol550,00 mg
The methylcellulose40,00 mg
Palmitostearate50,00 mg
Berry flavor40,00 mg
Ammonium glycyrrhizinate0.5 mg
Talc10,00 mg

Example VI - Soft gelatin capsules for the treatment of tumors of the cervix

Sanguinarine lutein10,00 mg
Soy lecithin50,00 mg
Beeswax50,00 mg
Ammonium glycyrrhizinate10,00 mg
Vegetable oil in sufficient quantity to800,00 mg

Example VII - Soft gelatin capsules for the treatment of tumors of the cervix

Sanguinarine lutein10,00 mg
Soy lecithin50,00 mg
Beeswax50,00 mg
Sodium succinyl-glycyrrhetic10,00 mg
Vegetable oil in sufficient quantity to800,00 mg

Example VIII - Emulsion oil-in-water salts fosfatidinozitol acid and sanguinarine for the local treatment of melanoma

Salt dipalmitoylphosphatidyl acid and sanguinarine0.40 g
Propylene glycol10,00 g
Isopropylmyristate5,00 g
Cetyl alcohol5,00 g
Polysorbate 803.00 g
Carbomer0.40 g
Methyl parahydroxybenzoate0.10 g
Sodium propyl parahydroxybenzoate 0.05 g
Purified water in sufficient quantity to100 g

1. The use of salts benzophenantridin alkaloids to obtain drugs for the treatment of tumors, where the alkaloid is in salt form luteomas, hyaluronic or phosphatidic acid.

2. The use according to claim 1, where benzophenantridin alkaloids selected from sanguinarine, chelerythrine, chelidonine.

3. The use according to claim 2, where the alkaloid is chelerythrine.

4. The use according to claim 1 of luteolata sanguinarine.

5. The use according to claim 1 salts of sanguinarine and phosphatidic acid.

6. Salt benzophenantridin alkaloids with phosphatidic acid or hyaluronic acid.

7. Salt according to claim 6 with phosphatidic acid.

8. Salt according to claim 7, where phosphatidic acid is dipalmitoyl or distearoylphosphatidylcholine acid.

9. Salt according to claim 7 or 8, where benzophenantridin alkaloid is a sanguinarine.

10. Salt according to claim 7 or 8 as antimelanoma tools.

11. Sol according to claim 9 as antimelanoma tools.

12. Pharmaceutical composition for the treatment of tumors containing salt p-11 as an active ingredient.


Same patents:

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to a recovered imidised biologically compatible polymer functionalised by an imide group. The above polymer is selected from the group consisting of polyethylene oxide, partially or completely hydrolysed by polyvinyl alcohol, polyvinylpyrrolidone, polyethyloxazoline, polyoxypropylene oxide block copolymers (poloxamers and meroxapol), polyethylene oxide and poloxamine copolymer, carboxymethyl cellulose and hydroxyalkylated cellulose, polypeptides, polysaccharides, carbohydrates, polysaccharose, hyaluronic acid, dextran, heparin sulphate, keratan sulphate, chondroitin sulphate, heparin, alginate, gelatin, collagen, albumin, ovalbumin, complex polyphosphoesters, polylactides, polyglycolides, polycaprolactones, polyamides, polyurethanes, polyesteramides, polyorthoesters, polydioxanones, polyacetals, polyketals, polycarbonates, polyorthocarbonates, polyphosphazenes, polyhydroxybutyrates, polyhydroxyvalerates, polyalkylene oxalates, polyalkylene succinates, polymaleic acids, polyamino acids, polyvinyl alcohol, polyvinylpyrrolidone, polyhydroxy cellulose, chitin, chitosan, and copolymers, ternary copolymers, or combinations or mixtures of the aforementioned materials. Also, the invention refers to a composition for a tissue adhesive, a medical device and a pharmaceutical composition.

EFFECT: invention represents additionally modified or functionalised imidised polymers.

9 cl, 2 ex, 20 dwg

FIELD: biotechnologies.

SUBSTANCE: fish roe is homogenised. Fish roe hydrolysis is carried out with a ferment preparation "Collagenase" in presence of an inhibitor for 10-12 hours. Chitosan is added to the produced hydrolysate at the ratio of 0.5-1.0:1.0. Components are mixed.

EFFECT: invention makes it possible to accelerate process of chitosan-nucleic complex production.

1 dwg, 1 tbl, 3 ex

FIELD: biotechnologies.

SUBSTANCE: method includes depolymerisation of a high-molecular chitosan with hydrogen peroxide. The process of chitosan depolymerisation is carried out in a double-phase system. The solid phase is activated chitosan with Mav = 450-650 kDa and the average particle size of 0.05-0.20 mm. The liquid phase is a water solution of H2O2 with concentration of H2O2 in a reaction system equal to 1-7%. The reaction is carried out for 120-180 minutes at 70C. Then phase separation of produced chitosan homologs is carried out by means of filtration via paper or textile surface of the produced reaction mixture. The produced filtrate contains water-soluble chitosan oligomers.

EFFECT: invention makes it possible to quantitatively control extent of conversion of an initial high-molecular chitosam into oligomer and low-molecular structures of its homologs.

1 tbl, 1 ex

FIELD: chemistry.

SUBSTANCE: invention relates to a method of purifying chondroitin sulphate and can be used in food and cosmetic industry and in medicine. The method involves electrochemical deposition to obtain a hydrogel of chondroitin sulphate, stabilisation, removal from the electrode, washing and drying. The chondroitin sulphate is dissolved in a 0.01-0.1 n alkali solution in ratio of 1:50-1:200 and deposited in an alkaline medium with constant cooling and stirring. The solution is stirred at a rate of 10-20 rpm. Current density is equal to 1-10 A/m2. Voltage is preferably not lower than 2.7 V. The hydrogel of chondroitin sulphate is stabilised in a 0.05-0.5 n HCl solution.

EFFECT: invention enables to obtain chondroitin sulphate with high weight ratio of the basic substance and increases output of the end product.

5 cl, 1 ex

FIELD: chemistry.

SUBSTANCE: present invention relates to a method of producing a N,S-cyclo-containing chitosan derivative. Described is a method of producing a chitosan-based N,S-cyclo-containing polymer (I) which contains in the macrochain 1-oxa-6-thia-4,8-diazocycloundecane fragments: I, by reacting chitosan with formaldehyde and a S-containing compound, characterised by that the S-containing compound used is hydrogen sulphide, the formaldehyde solution is pre-saturated with H2S and the reaction is carried out with molar ratio chitosan: formaldehyde: hydrogen sulphide of 1:2:1, at temperature of 0-60C in a chloride medium for 24 hours.

EFFECT: obtaining modified chitosan which exhibits properties of a highly efficient heavy metal sorbent for waste water treatment, an extractant for separating rare, noble and precious metals and a complexing agent for biological molecules.

1 tbl, 3 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to biochemistry. What is presented is a conjugate of hyaluronic acid and novocaine of a structure as defined in the patent claim containing 20-50% residues of novocaine.

EFFECT: conjugate is water-soluble; it possess the amphoteric properties and contains no side O-acylisourea.

3 tbl, 3 ex

FIELD: chemistry.

SUBSTANCE: disclosed are versions of a method of producing cross-linked polysaccharides, involving reaction of at least one polysaccharide selected from amino-polysaccharide, amino-functionalised polysaccharide containing one or more amino groups which can be cross-linked by reducing sugar, and combinations thereof, with at least one reducing sugar. The invention also discloses polysaccharides obtained using the disclosed method, a method of producing cross-linked matrices based on polysaccharides and matrices obtained using this method. The obtained matrices may include polysaccharide matrices and composite cross-linked matrices, including polysaccharides cross-linked with proteins and/or polypeptides.

EFFECT: obtained polysaccharides have satisfactory resistance to enzymatic degradation coupled with rheological properties of the preparation for injection, obtained matrices exhibit various physical, chemical and biological properties.

29 cl, 12 dwg, 6 tbl, 11 ex

FIELD: medicine.

SUBSTANCE: chitosan is dissolved in an organic acid: 4-6% citric acid or 2-8% lactic acid in the relation of the ingredients chitosan: the organic acid 1:2-1:4 to prepare a forming solution. Chitosan has molecular weight 80-500 kDa. The forming solution is added with vitamin B1 in the amount of max. 0.5 wt %. The prepared forming solution is applied on a substrate in the amount of 0.2-0.25 ml/cm2 and kept to achieve a film structure. Said method is used to form the chitosan film coating having the thickness of 50-250 mcm and the breaking elongation of 42 to 470%.

EFFECT: group of inventions allows preparing high-elastic chitosan citrate or lactate films possessing bactericidal action.

2 cl, 1 tbl, 13 ex

FIELD: chemistry.

SUBSTANCE: method involves preparation of material for enzymatic hydrolysis. Alkaline hydrolysis is carried out with proteolytic enzyme preparations with neutralisation of the obtained solution to pH=7. A salt is added to the obtained enzymatic hydrolysate to a value of not less than 0.1 mol/l. Successive ultrafiltration is carried out, first on a membrane with maximum retention of 50 kD with separation of high-molecular weight impurities, and then on a membrane with maximum retention of 5 kD with separation of low-molecular weight substances. The chondroitin sulphate solution retained at the membrane is washed on the same membrane with distilled water until complete removal of salts. Final washing with distilled water is carried out on a membrane with maxim retention of 50 kD.

EFFECT: invention enables to obtain a chondroitin sulphate preparation with weight ratio of the basic substance.

7 ex

FIELD: chemistry.

SUBSTANCE: method involves activation of hyaluronic acid using a cross-linking agent and an auxiliary cross-linking agent. The activated hyaluronic acid then reacts with a nucleophilic cross-linking agent. The pH of the reaction medium ranges from 8 to 12. The nucleophilic cross-linking agent contains at least 50 wt % oligopeptide or polypeptide. Further, pH of the reaction medium is regulated to 5-7 and cross-linked hyaluronic acid is precipitated in the organic solvent. The invention also relates to use of the cross-linked hyaluronic acid obtained using this method in plastic surgery to make implants and to a hedrogel containing said cross-linked hyaluronic acid in a buffer aqueous solvent.

EFFECT: invention enables to obtain cross-linked hyaluronic acid in dry form, having high resistance to decomposition factors such as temperature, free radicals and enzymes.

18 cl, 3 tbl, 3 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: present invention refers to pharmaceutical compositions containing synthetic oxidised lipids.

EFFECT: developing the method for using the oxidised lipids for treating and preventing the inflammation associated with the endogenous oxidised lipid.

39 cl, 11 tbl, 15 ex, 25 dwg

FIELD: chemistry.

SUBSTANCE: invention relates to a method of producing a lipid preparation which contains phosphatidylcholine (PC), phosphatidylethanolamine (PE), phosphatidylserine (PS) and phosphatidylinositol (PI), and sphyngomyelin (SM), a composition containing a mixture of said lipids and use thereof. The method involves steps of removing non-lipid material from bovine milk by dispersing the lipids in a mixture of a polar organic solvent and a nonpolar solvent, followed by separation of the lipid fraction and removing the solvent from said fraction, a step of de-oiling the obtained lipid fraction in order to remove nonpolar lipids by dissolving in acetone or supercritical CO2 and a step of filtering and drying the obtained lipids. In the lipid composition obtained using said method, the ratio of phospholipids is comparable with that of phospholipids in human breast milk. Disclosed is use of the composition obtained using the disclosed method as a source of human breast milk fat for making infant formula.

EFFECT: method enables to obtain a human breast milk substitute by processing readily available material and use thereof to make infant formula.

8 cl, 5 tbl, 1 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: claimed invention relates to application for production of medication for prevention and/or treatment of radiolesion or lesion of trisubstituted glycerol compound, corresponding to formula where X is selected from phosphate and sulfate; R1 is selected from C16-C20alkyl, R2 is selected from C1-C3alkyl and C1-C3hydroxyalkyl, R3 is selected from hydrogen and C1-C3 alkyl, R4 is selected from C1-C3alkyl and C3-C6cycloalkyl, R5 is selected from hydrogen and methyl, or its enantiomer, or diastereomer, or pharmaceutically acceptable salt, and at least one pharmaceutically acceptable filling agent.

EFFECT: claimed is novel application of known compounds.

12 cl, 3 dwg, 5 ex, 5 tbl

FIELD: chemistry.

SUBSTANCE: in the proposed methods, the hydroxyl group of the formula I compound is substituted with the corresponding residue so that use of column chromatography is avoided, , where A1 is CH2, R1 is alkyl, R3 is a residue of phosphoric acid, phosphorylcholine, phosphoryl ethanolamine, phosphorylserine, phosphoryl cardiolipin, phosphoryl inosite, ethylphosphocholine, phosphoryl methanol, phosphoryl ethanol, phosphoryl propanol, phosphoryl butanol, phosphoryl ethanolamine-N-lactose, phosphoethanolamine-N-[methoxy(propyleneglycol)], phosphoinosite-4-phosphate, phosphoinosite-4,5-biphosphonate, pyrophosphate, phosphoethanolaminediethylene-triaminepentaacetate, dinitrophenyl phosphoethanolamine, phosphogycerine or a reactive phosphorus-containing group which can convert to the said residues, or hydrogen.

EFFECT: design of methods of producing phospholipids, which avoid use of chromatography.

22 cl, 5 ex

FIELD: medicine.

SUBSTANCE: invention concerns the new synthetic oxidised lipids and ways of application of the oxidised lipids for treatment and inflammation prevention, associated with endogenous oxidised lipid.

EFFECT: rising of treatment efficiency.

54 cl, 25 dwg, 15 ex

FIELD: biotechnology.

SUBSTANCE: claimed method includes interaction of mixtures of natural phosphatides or components thereof, for instance, soybean or egg lecithin or animal phospholipids, or synthetic phosphatides, by reaction thereof with D phospholipase having transphosphatidylase activity in water medium.

EFFECT: simplified method for isolation of pure phosphatides of improved purity with increased yield.

28 cl, 13 ex

The invention relates to the field of medicine and for the application of hydrogenated soy phosphatidylcholine (Phospholipon-N) as an active ingredient, providing a surface-active properties of drugs for substitution of the surfactant therapy
The invention relates to an improved method for producing a water-soluble amino acid derivatives of fullerene that can be used in pharmacology and Microbiology

The invention relates to organic chemistry, namely the chemistry of fullerenes

FIELD: organic synthesis catalysts.

SUBSTANCE: catalyst consists of complex [Sm(NO3)5][C5H5NH]2 constituted by samarium nitrate, pyridine, and nitric acid taken in molar ratio 10:20:20, respectively.

EFFECT: achieved accessibility of catalyst.

1 tbl, 2 ex